Lanean...
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
PURPOSE: Antiproliferative and antiosteoclastic activity from preclinical models show potential for dasatinib, an oral SRC and SRC family kinase inhibitor, as a targeted therapy for patients with prostate cancer. This phase II study investigated the activity of dasatinib in patients with metastatic...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2009
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3394097/ https://ncbi.nlm.nih.gov/pubmed/19920114 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-1691 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|